Arimoclomol Safety Profile in the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Safety Data from an Expanded Access Program in the United States
Monday, February 3, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the long-term safety profile of Arimoclomol in treating Niemann-pick Disease Type C based on data from an expanded access program in the United States. The findings were presented at the 21st Annual WORLDSymposium. This real-world data may provide valuable insights into the drug's effectiveness and safety.
Price reaction · baseline $7.84 (2025-01-31 close) · hit pre-market · 2 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term safety data supports Arimoclomol's use.
Expanded access program provides real-world insights.
Potential benefits for Niemann-pick Disease Type C patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol Safety Profile in the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Safety Data from an Expanded Access Program in the United States
21st Annual WORLDSymposium - 02/05/2025
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used in the treatment of Niemann-pick Disease Type C.
What does the long-term safety data indicate?
The long-term safety data supports the positive safety profile of Arimoclomol.
Where was the safety data presented?
The safety data was presented at the 21st Annual WORLDSymposium.
What type of program provided the safety data?
The data comes from an expanded access program in the United States.